<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02651246</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 31915</org_study_id>
    <nct_id>NCT02651246</nct_id>
  </id_info>
  <brief_title>Optional Sub-study to Intraoperative Imaging With ICG Registry</brief_title>
  <official_title>Optional Sub-study to Intraoperative Imaging With ICG Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this optional sub-study is to record what tissues fluoresce in the&#xD;
      operating room, and then to identify if these lesions are cancer when the histopathology is&#xD;
      performed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our objective is to collect prospective data on cancer subjects who undergo surgery and&#xD;
      intraoperative imaging. The registry will include (but not limited to) cancer type, stage,&#xD;
      intraoperative challenges to the surgeon, usage and results of intraoperative imaging, and&#xD;
      recurrence surveillance.&#xD;
&#xD;
      In this protocol, subjects that receive intraoperative imaging will provide us the&#xD;
      opportunity to record what tissues fluoresce in the operating room, and then to identify if&#xD;
      these lesions are cancer when the histopathology is performed. Also, we will monitor any side&#xD;
      effects or potential toxicities that may occur. This data can then be used to predict if a&#xD;
      subject is more likely to develop a local recurrence due to missed cancer cells, metastatic&#xD;
      lymph nodes or synchronous lesions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">February 2020</completion_date>
  <primary_completion_date type="Actual">February 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>Number of tumor recurrence</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Actual">291</enrollment>
  <condition>Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer</condition>
  <condition>Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer</condition>
  <condition>Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>data collection</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        cancer patients who undergo surgery and intraoperative imaging&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients &gt;= 18 years of age&#xD;
&#xD;
          -  Patients presenting with any solid tumor and/or diseased tissue even benign nodules&#xD;
             presumed to be resectable and are at risk for recurrence.&#xD;
&#xD;
          -  Good operative candidate as determined by the treating physician and/or&#xD;
             multidisciplinary team&#xD;
&#xD;
          -  Subject capable of giving informed consent and participating in the process of&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women as determined by urinary or serum beta hCG within 72 hours of surgery&#xD;
&#xD;
          -  Vulnerable patient populations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunil Singhal, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 6, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2016</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromatosis, Aggressive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

